New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel

References

• DrakeLACeilleyRICornelisonRLGuidelines of care for actinic keratoses. Committee on Guidelines of CareJ Am Acad Dermatol199532195987529779
   PubMedGoogle Scholar
• Society for Investigative Dermatology, American Academy of Dermatology Association The burden of skin diseases, 2005. Available from: http://www.lewin.com/~/media/lewin/site_sections/publications/april2005skindisease. Accessed March 12, 2012.
   Google Scholar
• CockerellCJWhartonJRNew histopathological classification of actinic keratosis (incipient intraepidermal squamous cell carcinoma)J Drugs Dermatol20054446246716004019
   PubMedGoogle Scholar
• BermanBBienstockLKuritzkyLMayeauxEJJrTyringSKActinic keratoses: sequelae and treatments. Recommendations from a consensus panelJ Fam Pract5200655Suppl 51816672155
   PubMedGoogle Scholar
• SchwartzRAThe actinic keratosis. A perspective and updateDermatol Surg19972311100910199391557
   PubMed Web of Science ®Google Scholar
• EinspahrJGAlbertsDSWarnekeJARelationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesisNeoplasia19991546847510933063
   PubMedGoogle Scholar
• TollASalgadoRYebenesMMYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinomaBr J Dermatol200916151112111819673870
   PubMed Web of Science ®Google Scholar
• TollASalgadoRYebenesMEpidermal growth factor receptor gene numerical aberrations are frequent events in actinic keratoses and invasive cutaneous squamous cell carcinomasExp Dermatol201019215115320156290
   PubMed Web of Science ®Google Scholar
• KanellouPZaravinosAZiogaMGenomic instability, mutations and expression analysis of the tumour suppressor genes p14ARF, p15INK4b, p16INK4a and p53 in actinic keratosisCancer Lett2008264114516118331779
   PubMed Web of Science ®Google Scholar
• PadillaRSSebastianSJiangZNindlILarsonRGene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progressionArch Dermatol2010146328829320231500
   PubMedGoogle Scholar
• MarksRFoleyPGoodmanGHageBHSelwoodTSSpontaneous remission of solar keratoses: the case for conservative managementBr J Dermatol198611566496553801305
   PubMed Web of Science ®Google Scholar
• CriscioneVDWeinstockMANaylorMFLuqueCEideMJBinghamSFActinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention TrialCancer2009115112523253019382202
   PubMed Web of Science ®Google Scholar
• DodsonJMDeSpainJHewettJEClarkDPMalignant potential of actinic keratoses and the controversy over treatment. A patient-oriented perspectiveArch Dermatol19911277102910312064402
   PubMedGoogle Scholar
• CzarneckiDMeehanCJBruceFCuljakGThe majority of cutaneous squamous cell carcinomas arise in actinic keratosesJ Cutan Med Surg20026320720911951126
   PubMed Web of Science ®Google Scholar
• MittelbronnMAMullinsDLRamos-CaroFAFlowersFPFrequency of pre-existing actinic keratosis in cutaneous squamous cell carcinomaInt J Dermatol19983796776819762818
   PubMed Web of Science ®Google Scholar
• HurwitzRMMongerLESolar keratosis: an evolving squamous cell carcinoma. Benign or malignant?Dermatol Surg19952121847894943
   PubMed Web of Science ®Google Scholar
• FeldmanSRFleischerABJrProgression of actinic keratosis to squamous cell carcinoma revisited: clinical and treatment implicationsCutis201187420120721644496
   PubMed Web of Science ®Google Scholar
• StockflethEFerrandizCGrobJJLeighIPehambergerHKerlHDevelopment of a treatment algorithm for actinic keratoses: a European consensusEur J Dermatol200818665165918955209
   PubMed Web of Science ®Google Scholar
• DinehartSMThe treatment of actinic keratosesJ Am Acad Dermatol2000421 Pt 2252810607354
   PubMed Web of Science ®Google Scholar
• HalpernACHansonLJAwareness of, knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physiciansInt J Dermatol200443963864215357741
   PubMed Web of Science ®Google Scholar
• BalkrishnanRCayceKAKulkarniASPredictors of treatment choices and associated outcomes in actinic keratoses: results from a national physician survey studyJ Dermatolog Treat200617316216616854758
   PubMed Web of Science ®Google Scholar
• ThaiKEFerginPFreemanMA prospective study of the use of cryosurgery for the treatment of actinic keratosesInt J Dermatol200443968769215357755
   PubMed Web of Science ®Google Scholar
• KrawtchenkoNRoewert-HuberJUlrichMMannISterryWStockflethEA randomised study of topical 5% imiquimod vs topical 5-fluorouracil vs cryosurgery in immunocompetent patients with actinic keratoses: a comparison of clinical and histological outcomes including 1-year follow-upBr J Dermatol2007157Suppl 2344018067630
   PubMed Web of Science ®Google Scholar
• TanghettiEWerschlerPComparison of 5% 5-fluorouracil cream and 5% imiquimod cream in the management of actinic keratoses on the face and scalpJ Drugs Dermatol20076214414717373172
   PubMedGoogle Scholar
• UlrichMKrueger-CorcoranDRoewert-HuberJSterryWStockflethEAstnerSReflectance confocal microscopy for noninvasive monitoring of therapy and detection of subclinical actinic keratosesDermatology20102201152419907131
   PubMed Web of Science ®Google Scholar
• RiversJKArletteJShearNGuentherLCareyWPoulinYTopical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gelBr J Dermatol200214619410011841372
   PubMed Web of Science ®Google Scholar
• SwansonNAbramovitsWBermanBKulpJRigelDSLevySImiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 2-week cyclesJ Am Acad Dermatol201062458259020133013
   PubMed Web of Science ®Google Scholar
• LovenKSteinLFurstKLevySEvaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosisClin Ther2002246990100012117087
   PubMed Web of Science ®Google Scholar
• WerschlerWPConsiderations for use of fluorouracil cream 0.5% for the treatment of actinic keratosis in elderly patientsJ Clin Aesthet Dermatol200812222721103319
   PubMedGoogle Scholar
• LeeADJorizzoJLOptimizing management of actinic keratosis and photodamaged skin: utilizing a stepwise approachCutis200984316917519842577
   PubMed Web of Science ®Google Scholar
• Serra-GuillénCNagoreEHuesoLA randomized pilot comparative study of topical methyl aminolevulinate photodynamic therapy versus imiquimod 5% versus sequential application of both therapies in immunocompetent patients with actinic keratosis: clinical and histologic outcomesJ Am Acad Dermatol2012664e131e13722226430
   PubMed Web of Science ®Google Scholar
• BerlinJMRigelDSDiclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgeryJ Drugs Dermatol20087766967318664159
   PubMed Web of Science ®Google Scholar
• TanJKThomasDRPoulinYMaddinFTangJEfficacy of imiquimod as an adjunct to cryotherapy for actinic keratosesJ Cutan Med Surg200711619520118042331
   PubMed Web of Science ®Google Scholar
• JorizzoJLMarkowitzOLebwohlMGA randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratosesJ Drugs Dermatol2010991101110820865842
   PubMed Web of Science ®Google Scholar
• JorizzoJWeissJVamvakiasGOne-week treatment with 0.5% fluorouracil cream prior to cryosurgery in patients with actinic keratoses: a double-blind, vehicle-controlled, long-term studyJ Drugs Dermatol20065213313916485881
   PubMedGoogle Scholar
• Picato (ingenol mebutate) gel 0.015%, 0.05% [package insert]Parsippany, NJLEO Pharma Inc.2012
   Google Scholar
• WeedonDChickJHome treatment of basal cell carcinomaMed J Aust1976124928979751
   PubMed Web of Science ®Google Scholar
• GreenACBeardmoreGLHome treatment of skin cancer and solar keratosesAustralas J Dermatol19882931271303272119
   PubMedGoogle Scholar
• RamsayJRSuhrbierAAylwardJHThe sap from Euphorbia peplus is effective against human nonmelanoma skin cancersBr J Dermatol2011164363363621375515
   PubMed Web of Science ®Google Scholar
• ZibertJRBertelsenMGrue-SørensenGIngenol mebutate penetrates reconstructed human skin in a gradient dependent manner and clears subclinical skin cancerPoster P5501 presented at the Annual Meeting of the American Academy of DermatologyMarch 16–20, 2012San Diego, CA
   Google Scholar
• OgbourneSMSuhrbierAJonesBAntitumor activity of 3-ingenyl angelate: plasma membrane and mitochondrial disruption and necrotic cell deathCancer Res20046482833283915087400
   PubMed Web of Science ®Google Scholar
• StahlhutMLordJMBertelsenMIngenol mebutate initiates multiple specific cell death pathways in human cancer cellsPoster P5517 presented at the Annual Meeting of the American Academy of DermatologyMarch 16–20, 2012San Diego, CA
   Google Scholar
• KedeiNLundbergDJTothAWelburnPGarfieldSHBlumbergPMCharacterization of the interaction of ingenol 3-angelate with protein kinase CCancer Res20046493243325515126366
   PubMed Web of Science ®Google Scholar
• HampsonPChahalHKhanimFPEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKCBlood200510641362136815845901
   PubMed Web of Science ®Google Scholar
• SerovaMGhoulABenhadjiKAEffects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cellsMol Cancer Ther20087491592218413805
   PubMed Web of Science ®Google Scholar
• BenhadjiKASerovaMGhoulAAntiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cellsBr J Cancer200899111808181519034280
   PubMed Web of Science ®Google Scholar
• ChallacombeJMSuhrbierAParsonsPGNeutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelateJ Immunol2006177118123813217114487
   PubMed Web of Science ®Google Scholar
• LiLShuklaSLeeAThe skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multi-drug transporter (ABCB1) and targets tumor vasculatureCancer Res201070114509451920460505
   PubMed Web of Science ®Google Scholar
• FeckerLFStockflethEBraunFKEnhanced death ligand-induced apoptosis in cutaneous SCC cells by treatment with diclofenac/ hyaluronic acid correlates with downregulation of c-FLIPJ Invest Dermatol201013082098210920237495
   PubMed Web of Science ®Google Scholar
• HampsonPKavanaghDSmithEWangKLordJMEdRGThe anti-tumor agent, ingenol-3-angelate (PEP005), promotes the recruitment of cytotoxic neutrophils by activation of vascular endothelial cells in a PKC-delta dependent mannerCancer Immunol Immunother20085781241125118265980
   PubMed Web of Science ®Google Scholar
• LeTTGardnerJHoang-LeDImmunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapiesVaccine200927233053306219428919
   PubMed Web of Science ®Google Scholar
• LeeWYHampsonPCoulthardLNovel antileukemic compound ingenol 3-angelate inhibits T cell apoptosis by activating protein kinase C thetaJ Biol Chem201028531238892389820472553
   PubMed Web of Science ®Google Scholar
• CozziSJOgbourneSMJamesCIngenol mebutate field-directed treatment of UVB-damaged skin reduces lesion formation and removes mutant p53 patchesJ Invest Dermatol201213241263127122189786
   PubMed Web of Science ®Google Scholar
• Kane-MaguireNCozziSJOgbourneSMMoselyRModulation of fibroblast phenotype and extracellular matrix composition by ingenol mebutate may be associated with scar resolution and improved dermal cosmesisPoster P5350 presented at the Annual Meeting of the American Academy of DermatologyMarch 16–20, 2012San Diego, CA
   Google Scholar
• SillerGGebauerKWelburnPKatsamasJOgbourneSMPEP005 (ingenol mebutate) gel, a novel agent for the treatment of actinic keratosis: results of a randomized, double-blind, vehicle-controlled, multi-centre, Phase IIa studyAustralas J Dermatol2009501162219178487
   PubMed Web of Science ®Google Scholar
• AndersonLSchmiederGJWerschlerWPRandomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosisJ Am Acad Dermatol200960693494319467365
   PubMed Web of Science ®Google Scholar
• LebwohlMSwansonNAndersonLLMelgaardAXuZBermanBIngenol mebutate gel for actinic keratosisN Engl J Med2012366111010101922417254
   PubMed Web of Science ®Google Scholar
• BermanBMarmurEMelgaardAThree-day topical treatment with ingenol mebutate gel 0.015% for actinic keratoses on the face and scalp: analysis of data pooled from two trialsPoster P5623 presented at the Annual Meeting of the American Academy of DermatologyMarch 16–20, 2012San Diego, CA
   Google Scholar
• AndersonLLSchmeiderGJXuZMelgaardATwo-day topical treatment with ingenol mebutate gel 0.05% for actinic keratoses on the trunk and extremities: analysis of data pooled from two trialsPoster P5640 presented at the Annual Meeting of the American Academy of DermatologyMarch 16–20, 2012San Diego, CA
   Google Scholar
• JarrattMA randomized, double-blind, vehicle-controlled study to evaluate the pharmacokinetics of PEP005 (ingenol mebutate) gel, 0.05%, when applied to dorsal forearms with multiple actinic keratoses (AK) in a maximal-use setting, defined as a contiguous 100-cm2 area of skinPoster presented at the 7th Annual Orlando Dermatology Aesthetic and Clinical meetingJanuary 15–18, 2010Orlando, FL
   Google Scholar
• HankeCWBeerKRStockflethEWuJRosenTLevySImiquimod 2.5% and 3.75% for the treatment of actinic keratoses: results of two placebo-controlled studies of daily application to the face and balding scalp for two 3-week cyclesJ Am Acad Dermatol201062457358120133012
   PubMed Web of Science ®Google Scholar
• WolfJEJrTaylorJRTschenEKangSTopical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosesInt J Dermatol2001401170971311737438
   PubMed Web of Science ®Google Scholar
• RiversJKArletteJShearNGuentherLCareyWPoulinYTopical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gelBr J Dermatol200214619410011841372
   PubMed Web of Science ®Google Scholar
• WeissJMenterAHeviaOEffective treatment of actinic keratosis with 0.5% fluorouracil cream for 1, 2, or 4 weeksCutis200270Suppl 2222912353677
   PubMed Web of Science ®Google Scholar